

BK



(11) Publication number: **0 414 134 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

- (45) Date of publication of patent specification: **02.11.94** (51) Int. Cl.⁵: **C12N 15/29, C12N 15/62, C12N 1/21, //(C12N1/21, C12R1:19)**
- (21) Application number: **90115718.0**
- (22) Date of filing: **16.08.90**

(54) **Method for producing antiviral protein utilizing E.coli transformant, and gene and E.coli vector used in the method.**

- (30) Priority: **17.08.89 JP 210767/89**
- (43) Date of publication of application: **27.02.91 Bulletin 91/09**
- (45) Publication of the grant of the patent: **02.11.94 Bulletin 94/44**
- (84) Designated Contracting States: **DE FR GB**
- (56) References cited:
EP-A- 0 314 184
DE-A- 3 735 380
- JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 264, no. 12, 25 April 1989, Baltimore, US, pp. 6629-6637; HABUKA et al.: "Amino Acid Sequence of MIRABILIS Antiviral Protein, Total Synthesis of Its Gene and Expression in ESCHERICHIA coli"**

- (73) Proprietor: **Japan Tobacco Inc.**
2-1 Toranomon, 2-Chome
Minato-Ku Tokyo 105 (JP)
- (72) Inventor: **Habuka, Noriyuki, c/o JAPAN TO-BACCO INC.**
Life Science Research Laboratory,
6-2, Umeaoka
Midori-ku, Yokohama-shi (JP)
 Inventor: **Akiyama, Kiyotaka, c/o JAPAN TO-BACCO INC.**
Life Science Research Laboratory,
6-2, Umeaoka
Midori-ku, Yokohama-shi (JP)
 Inventor: **Tsuge, Hideaki, c/o JAPAN TOBACCO INC.**
Life Science Research Laboratory,
6-2, Umeaoka
Midori-ku, Yokohama-shi (JP)
 Inventor: **Matsumoto, Takashi, c/o JAPAN TO-BACCO INC.**
Life Science Research Laboratory,
6-2, Umeaoka
Midori-ku, Yokohama-shi (JP)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 414 134 B1

JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 265, no. 19, 5 July 1990, Baltimore, US, pages 10988-10992, HABUKA N. et al: "Expression and Secretion of MIRABILIS Antiviral Protein...Prokaryotic Protein Synthesis"

FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES, vol. 244, no. 2, 27 February 1989, Amsterdam, pages 383 - 387; HUSSAIN K. et al: "Expression of ricin B chain in ES-CHERICHIA coli "

Inventor: Noma, Masana, c/o JAPAN TOBACCO INC.
Life Science Research Laboratory,
6-2, Umegaoka
Midori-ku, Yokohama-shi (JP)

⑦ Representative: Sajda, Wolf E., Dipl.-Phys. et al
MEISSNER, BOLTE & PARTNER
Widenmayerstrasse 48
D-80538 München (DE)

D scription

This invention relates to a method for producing Mirabilis Antiviral Prot in.

Inventors of the present invention previously separated novel basic protein from Mirabilis jalapa and found that this protein showed antiviral activity (Published Unexamined Japanese Patent Application No. 243100/85). Specifically, this protein is Mirabilis Antiviral Protein (hereafter abbreviated as MAP). The inventors also cultured tissues of Mirabilis jalapa and succeeded in production of MAP utilizing the cultured tissue which obtained (Published Unexamined Japanese Patent Application Nos. 125382/87 and 269710/86).

MAP can be mass-produced industrially and easily by growing a large amount of Mirabilis jalapa and extracting MAP therefrom. However, this method has the disadvantage that both much time and an extensive planted area are required for growing Mirabilis jalapa. Methods utilizing cultured tissue disclosed in said Published Unexamined Japanese Patent Application Nos. 125382/87 and 269710/86 also require a long period of ca. 12 days for cell culture.

Meanwhile, with a rapid improvement of gene manipulation techniques, cloning techniques, etc. in recent years, productions of available substances using genetic engineering have been tried. Many trials have attained success. Additionally, in protein engineering, genetic approach is becoming important to study novel proteins. This is due to improvements of analyzing technique and DNA synthetic technique which are accomplished by accumulating fundamental studies.

Under the circumstances as said, some trials have been made in study of MAP to analyze the structure of MAP, to design MAP gene based on the analyzed MAP structures, and to synthesize it. The present inventors have also made the most of gene recombination and developed a method for producing MAP by introducing foreign genes into e.g. E.coli to produce MAP therein.

This method, however, suffers from the disadvantage that MAP produced and stored in E.coli inhibits biosynthesis of protein of E.coli itself. Therefore, growth of E.coli is inhibited and the amount of MAP produced therein does not readily increase, which limits the production of MAP.

On the other hand, in order to separate protein which accumulates in E.coli, a method is conventionally known to make a gene of signal peptide combine with gene for coding the objective protein and induce the produced protein to secret. Although many signal peptides are known, it requires practical experiments at present to know whether the desired effect can be obtained.

It is an object of the invention to provide a method for producing MAP which does not inhibit the growth of E.coli.

It is also an object of the invention to provide a gene which codes for MAP and is utilized as a foreign gene for said method for producing MAP.

It is a further object of the invention to provide recombinant plasmid which is integrated with said gene and is utilized as a vector in said method for producing MAP.

A method for producing MAP according to the present invention utilizes a gene as a foreign gene which is formed by making a gene for coding outer membrane protein OmpA signal peptide as shown in Fig. 1 combine with MAP gene having a nucleotide sequence as shown in Fig. 2 at its 5'-terminal. This method introduces the foreign gene into E.coli to transform it. This introduction uses a recombinant plasmid which is formed by integrating said foreign gene into a plasmid having E.coli expression system. The E.coli thus transformed produces MAP by expression of said gene, and also extracellularly transfer produced MAP. Therefore, no MAP accumulates in E.coli and growth of E.coli is not inhibited.

This invention can be more fully understood from the following detailed description when taken in conjunction with the accompanying drawings, in which:

Fig. 1 shows a signal sequence of OmpA and a nucleotide sequence for coding the signal sequence;
Fig. 2 shows a nucleotide sequence of a synthetic gene for coding MAP;
Fig. 3 shows a nucleotide sequence of a synthetic DNA linker; and
Figs. 4A to 4C show processes for forming a DNA vector including MAP gene and gene for coding the signal sequence according to an preferable embodiment of the present invention.

Preferable E.coli plasmid for utilizing as a vector in the invention maintains a number of copies in E.coli and includes a gene marker which make the bacteria to be resistant against antibiotics, etc.. Examples of the plasmids are pUC19, pBBR322, pKK223-3 and pTTQ19 plasmids, and other plasmid obtained by fusing some plasmids or by partially deleting bases from any one of the plasmids can also be used. An example of a fused plasmid is formed by fusing a region including replication origin (ori) and a part of ampicillin-resistance gene region (Ap) (i.e. a fragment obtained by digesting with restriction enzyme PvuI and PvuII) of pUC19, and a part of Ap, tac promoter region and rrnBT₁T₂ terminator region (i.e. a fragment obtained by complete digestion using PvuI and partial digestion using BamHI) of pKK223-3.

A vector for introducing a foreign gene which is to be expressed in E.coli generally requires the following DNA sequence other than the gene to be introduced:

(a) a region for operating transcription (operator)

(b) a region for promoting initiation of gene transcription (promoter);

5 Examples of promoters which are known to manifest in E.coli are N25 promoter and P_L promoter both of which are derived from coliphage, etc.. The P_L promoter is derived from E.coli lambda-phage and is known to be repressed by a control protein which is called cl. The cl includes temperature-sensitive mutant, called cl₈₅₇, which represses P_L promoter at 30°C, like the cl, but loses its repressing ability at 42°C, resulting in P_L promoter turn on. Accordingly, if an expression vector introduced in E.coli includes 10 both P_L promoter and cl₈₅₇ repressor gene, E.coli can be grown by culturing it at 30°C such that P_L promoter is repressed. Also, P_L promoter can be turned on to initiate transcription of the gene by culturing E.coli at 42°C.

The P_L promoter can be obtained by digesting lambda-phage gene or disclosed pPL-lambda plasmid with restriction enzyme BamHI and HpaI. The cl₈₅₇ repressor gene can be obtained by digesting gene of 15 lambda-phage mutant (cl₈₅₇, Sam 7) with restriction enzyme BglII and BanIII.

(c) a region for instructing termination of transcription (terminator)

Examples of known terminators are tL1 terminator derived from coliphage, rrnBT1₂ terminator derived from ribosome gene of E.coli, etc..

(d) a region for instructing initiation position of transcription after transcribing into mRNA (Shine-Dalgarno, SD sequence) 20

A sequence which is common to construction gene of E.coli can be used as SD sequence.

(e) methionine codon which is linked to the SD sequence and is for initiation of translation (ATG)

A. Formation of E.coli expression vector

25 An expression vector derived from plasmid DNA can be formed by deletion or insertion of a specific region from and in the plasmid DNA. The deletion and insertion can be performed by cleaving the plasmid at specific sites and combining the resultant fragments by means of an appropriate treatment. Specifically, appropriate utilization of synthetic DNA fragments enables restriction enzyme sites, SD sequence, gene for 30 coding amino acid sequence of protein, etc. which are not included in the original plasmid DNA to introduce.

For example, by making the DNA fragment and its complementary chain which are shown in Fig. 3 and include XbaI and BanIII sites that are not included in plasmid pKK223-3 to combine with a cleavage 35 fragment (a large fragment) which is obtained by digesting the pKK223-3 with EcoRI-HindIII, the restriction sites of XbaI and BanIII can be introduced in the pKK223-3. Additionally, by utilizing this pKK223-3 which includes restriction sites of XbaI and BanIII and a fully synthetic MAP gene also having XbaI and BanIII sites in its 5'- and 3'-terminals respectively, the fully synthetic MAP gene can be introduced into the plasmid pKK223-3. Further, SD sequence and a codon for coding a methionine residue which is required for 40 initiating transcription of gene can also be introduced into said plasmid at this time. Moreover, since restriction site of NdeI (CATATG) includes a methionine codon (ATG) in, a gene for coding other proteins can be introduced through this site.

Required DNA fragments can be synthesized by a DNA synthesizer. An expression vector is formed by combining DNA fragments obtained by the DNA synthesizer, those obtained by restriction enzyme 45 cleavage, and such a DNA fragment as needed obtained by converting a cohesive end into a flush end utilizing T4 DNA polymerase, DNA polymerase Klenow fragment, etc.. Each fragment can be combined by T4 DNA ligase or a commercially available ligation kit including the DNA ligase.

B. Formation of Secretory MAP Gene

50 OmpA is an outer membrane protein of E.coli and comprises a signal sequence as shown in Fig. 1. A nucleotide sequence of a gene for coding this signal sequence is also shown in Fig. 1. This signal sequence functions to make OmpA to secrete from E.coli. Therefore, by linking this signal sequence to N-terminal of other protein, the protein can be transferred outside from inside of the E.coli. For example, by linking the signal sequence shown in Fig. 1 to N-terminal of MAP, MAP can be secreted from E.coli.

55 Further, a gene for coding the signal sequence has the first methionine codon included in a part of said NdeI sites, and thus a foreign gene can be introduced into an expression vector having the NdeI site which is downstream from a promoter.

Fig. 1 also shows a sequence of three amino acid of MAP N-terminal and a DNA sequence corresponding thereto. C. Production of MAP utilizing *E.coli* transformant.

According to the method as said, an expression vector can be prepared which is introduced with e.g. P_L promoter, cl_{857} gene, and a gene for coding a protein. This vector can be further utilized to transform *E.coli* by a disclosed method, e.g. by the calcium chloride method.

A medium for culturing the transformants may contain carbon source, nitrogen source, minerals and, on an as-needed basis, minor organic nutrition source such as amino acids, vitamins, etc..

The transformants can be cultured e.g. in a liquid medium under the aerobic condition by e.g. stirring with aeration, with 6.5 - 8.5 of pH maintained. The culture is performed for several hours to ca. four days to produce MAP and to allow it accumulated in a medium.

Next, the medium containing MAP obtained as said is condensed. The resultant solution is subjected to an appropriate combination of salting out, ion exchange chromatography, gel filtration, affinity chromatography, etc. to purify MAP.

One example is that a MAP gene or a gene obtained by combining MAP gene and a gene for coding signal sequence is inserted into an expression vector including P_L promoter and cl_{857} gene, and this vector is introduced into *E.coli*, allowing generation of MAP, firstly by culturing the transformed *E.coli* under the aerobic condition at 30°C to fully grow the bacteria, and immediately after that increasing a culture temperature to 42°C, followed by further culture under the aerobic condition. MAP can be thus efficiently produced.

MAP thus produced can be determined by an immunological technique utilizing anti-MAP antibodies.

Although the following is to describe the present invention in detail with reference to preferable embodiments, it is to be understood that the invention is not restricted to the description. To understand the following embodiments, processes of forming DNA vector in the embodiments are shown in Figs. 4A to 4C.

25 A Step of Inserting A Synthetic DNA Fragment into Plasmid pKK223-3

A DNA linker containing restriction enzyme sites, SD sequence, methionine codon, and coding N-terminal amino acid sequence of MAP shown in Fig. 3 was inserted into plasmid pKK223-3 (manufactured by Pharmacia Japan Co., Ltd).

One micro gram of pKK223-3 was incubated in High Buffer (a mixture of 50mM Tris-HCl [pH7.5]-100mM of NaCl-1mM of MgCl₂) containing 10 units of each restriction enzyme of *EcoRI* and *HindIII* (manufactured by Nippon Gene Co. Ltd.) at 37°C for one hour for digestion. The obtained solution was subjected to phenol-chloroform treatment and ethanol precipitation to collect DNA. The phenol-chloroform treatment is described in detail as follows. Firstly, phenol was saturated with a mixture (hereinafter abbreviated as TE) of 10mM of Tris HCl (pH8.0) and 1mM of ethylenediamine tetra acetic acid (EDTA). The equivalent volume of the resultant phenol solution was added to the obtained DNA solution for mixing, and the resultant mixture was centrifuged to collect a aqueous phase containing DNA. Next, an equivalent volume of chloroform was added to this aqueous phase for further mixing, and the resultant mixture was centrifuged to collect an aqueous phase containing DNA. Ethanol precipitation is described in detail as follows. Firstly, to the obtained solution containing DNA, 5M of sodium chloride of 1/20-fold volume and ethanol of 2-fold volume were added, and the resultant mixture was cooled at -70°C for thirty minutes. Next, this solution was centrifuged at high speed to separate the obtained precipitant.

Two kind of single-stranded synthetic DNA linkers of complementary nucleotide sequences shown in Fig. 3 were prepared by utilizing the DNA synthesizer (manufactured by Applied Biosystems Japan Company, 381A-type) according to the phosphoramidite method. One microgram of each obtained synthetic linker was incubated in 100 μ l of a kinase solution (a mixture of 50mM of Tris HCl [pH7.6], 10mM of MgCl₂, 5mM of dithiothreitol, 0.1mM of spermidine, 0.1mM of EDTA, and 1mM of ATP) containing 10 unites of T4 kinase (manufactured by Toyobo Co., Ltd.) at 37°C for one hour to add phosphoric acid to 5'-terminal of the linkers. After that, the obtained single-stranded DNA was converted into double-stranded DNA by annealing. This annealing was performed by mixing the obtained reacted solutions, heating the resultant mixture at 60°C for twenty minutes, and allowing it to stand at room temperature for twenty minutes. Next, the resultant solution was subjected to ethanol precipitation, and then the precipitate was dissolved in 10 μ l of TE.

To 5 μ l of the thus obtained solution containing double-stranded synthetic DNA, 2.5 μ l of (ca. 0.5 μ g) of pKK223-3 cleavage product was added and the mixture was ligated at 10°C for two hours utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd). Plasmid pKS2 was then obtained by introducing the synthetic DNA linker into the plasmid pKK223-3.

A Step of Converting Replication Origin of pKS2 to that of plasmid pUC19 Type

Two microgram of plasmid pKS2 and restriction enzyme BamH1 were incubated at 37°C for one hour in 50 µl of High Buffer for digestion. Next, the obtained solution was subjected to phenol-chloroform treatment and ethanol precipitation to collect cleaved DNA. The obtained precipitate was added to 25 µl of Klenow solution (which is obtained by adding 0.1mM of each co-factor dATP, dGTP, dCTP and TTP to a mixture of 50mM of Tris-HCl [pH7.2], 10mM of MgSO₄, 0.1mM of dithiothreitol, and bovine serum albumin of 50 µg/ml), and the resultant solution was incubated at 22°C for 30 minutes to convert a cohesive end of the DNA to a flush end. After reaction, the solution was heated at 70°C for five minutes, followed by phenol-chloroform treatment and ethanol precipitation to collect DNA. The collected DNA was further cleaved by dissolving it in 50 µl of High Buffer containing 10 units of restriction enzyme PvuII (manufactured by Toyobo Co., Ltd.) at 37°C for one hour. The cleaved DNA was collected by phenol-chloroform treatment followed by ethanol precipitation.

Separately, 1 µg of plasmid pUC 19 (manufactured by Takara Syuzo Co., Ltd.) was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme PvuII (manufactured by Toyobo Co., Ltd.) and PvuII (manufactured by Nippon Gene Co., Ltd.) at 37°C for two hours to cleave pUC19. The cleaved DNA fragments were collected by phenol-chloroform treatment, followed by ethanol precipitation.

The DNA fragments (larger fragments) derived from pKS2 and DNA fragments derived from pUC19 both of which were obtained as mentioned were dissolved in 10 µl of TE, respectively. After that, each 3.5 µl of the TE solutions were mixed and the fragments was ligated at 10°C for one hour utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.) to obtain plasmid pKS3. This pKS3 comprises the replication origin of pUC19 and the large fragment of pKS2 which are combined therein.

A Step of Inserting P_L Promotor into pKS3

Two micrograms of pKS3 was incubated in 50 µl of High Buffer containing 10 units of a restriction enzyme PstI (manufactured by Nippon Gene Co., Ltd.) at 37°C for one hour for digestion. The cleaved DNA fragment was collected by phenol-chloroform treatment followed by ethanol precipitation. The collected DNA fragment was incubated in 20 µl of polymerase solution (which was obtained by adding 0.1mM of each co-factor of dATP, dGTP, dCTP and TTP to a mixture of 33mM of Tris-HCl [pH7.9], 66mM of potassium phosphate, 10mM of magnesium acetate, 0.5mM of dithiothreitol, and 0.1mg/ml of bovine serum albumin) containing 2.5 units of T4 DNA polymerase (manufactured by Toyobo Co., Ltd.) at 37°C for five minutes to convert a cohesive end of the DNA fragment to a flush end. Next, 1 µl of 0.5M EDTA was added to the resultant solution, and the obtained mixture was subjected to phenol-chloroform treatment and further ethanol precipitation to collect DNA. The collected DNA was incubated in 50 µl of High Buffer containing 10 units of restriction enzyme BamHI (manufactured by Nippon Gene Co., Ltd.) at 37°C for one hour for additional digestion.

Separately, 1 µg of pPL-lambda (manufactured by Pharmacia Co., Ltd.) was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme BamHI and HpaI (both manufactured by Nippon Gene Co., Ltd.) at 37°C for one hour for digestion. Next, the mixture was subjected to phenol-chloroform treatment and the following ethanol precipitation to collect DNA fragment containing the P_L promotor.

The DNA fragment derived from pKS3 and the DNA fragment containing the P_L promotor were dissolved in 10 µl of TE, respectively. Next, 3.5 µl of each solution obtained as said were mixed, and the DNA fragments therein were ligated utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.). After that, the resultant DNA was utilized to transform E.coli (strain HB101). From the obtained transformants, plasmid pSH4 was prepared. This plasmid pSH4 is the plasmid which was formed by inserting the P_L promotor into pKS3.

A Step of Cleaving out cI857 Gene form Lambda-phage DNA

Two microgram of lambda-phage (lambda, cI857, Sam7) DNA (manufactured by Takara Syuzo Co., Ltd.) was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme BgIII (manufactured by Nippon Gene Co., Ltd.) and BanIII (manufactured by Toyobo Co., Ltd.) at 37°C for two hours for digestion. The obtained DNA fragments were collected by phenol-chloroform treatment followed by ethanol precipitation.

Meanwhile, 1 µg of plasmid pHSG397 (manufactured by Takara Syuzo Co., Ltd.) was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme BamHI (Nippon Gene Co., Ltd.) and BanIII

(manufactured by Toyobo Co., Ltd.) at 37°C for one hour for digestion. Next, to the mixture, 2 µl (1 unit) of alkaline phosphatase (manufactured by Toyobo Co., Ltd.) was added, and the resultant mixture was allowed to heat at 60°C for 30 minutes for dephosphorylation at 5'-terminal of the DNA. After that, the DNA was collected by phenol-chloroform treatment and the following ethanol precipitation.

- 5 The lambda-phage DNA cleavage product and the pHS397 cleavage product both of which were thus obtained were dissolved in each 10 µl of TE. Next, 3.5 µl of each solution were mixed and the DNA cleavage products therein were ligated by reacting the mixture at 10°C for two hours utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.). The obtained DNA was utilized to transform *E. coli* (strain HB101), and plasmid DNA was purified from the obtained transformants. This plasmid DNA is pHS397 formed by inserting BglIII-BanIII fragment of ca.1100 base pairs including cl₈₅₇ into pHS397.

A Step of Inserting cl₈₅₇ into pSH4

- 15 Two micrograms of pHS397 was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme XhoI (manufactured by Nippon Gene Co., Ltd.) and BanIII (manufactured by Toyobo Co., Ltd.) at 37°C for one hour for digestion. The cleaved DNA fragments were collected by phenol-chloroform treatment and the following ethanol precipitation. The collected DNA was incubated in 25 µl of Klenow solution containing two units of Klenow fragment at 22°C for 30 minutes to convert a cohesive end of the DNA to a flush end. Next, the resultant solution was heated at 70°C for five minutes and subjected to phenol-chloroform treatment and the following ethanol precipitation to collect the DNA.

- 20 On the other hand, 1 µg of pSH4 was incubated in 50 µl of High Buffer containing 10 units of restriction enzyme BamHI (manufactured by Nippon Gene Co., Ltd.) at 37°C for one hour for digestion. The cleaved DNA was collected by phenol-chloroform treatment and the following ethanol precipitation. The collected DNA was incubated in 25 µl of Klenow solution containing 2 units of Klenow fragment at 22°C for 30 minutes to convert a cohesive end of the DNA to a flush end. Next, the resultant solution was heated at 70°C for five minutes, and subjected to phenol-chloroform treatment and the following ethanol precipitation to collect the resultant DNA.

- 25 The DNA fragments including cl₈₅₇ and the cleaved pSH4 fragments both of which were thus obtained were dissolved in 10 µl of TE, respectively. Next, 3.5 µl of each solution was mixed and the DNA fragments were ligated by reacting the solution at 10°C for two hours utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.). The obtained DNA was utilized to transform *E. coli* (strain HB101), and plasmid DNA was purified from the obtained transformants. The obtained plasmid is pSH5 formed by inserting cl₈₅₇ into plasmid pSH4.

- 35 A Step of Inserting a Complete Synthetic MAP Gene into pSH5

- Two micrograms of pSH5 was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme XbaI (manufactured by Nippon Gene Co., Ltd.) and BanIII (manufactured by Toyobo Co., Ltd.) at 37°C for one hour for digestion. The resultant solution was subjected to phenol-chloroform treatment and the following ethanol precipitation to collect the cleaved DNA.

Meanwhile, 2 µg of pMHI was digested and the cleaved DNA was collected by the same manner as said for pSH5. The pMHI here is a synthetic plasmid formed by inserting a complete synthetic MAP gene into the plasmid pUC19.

- 45 The DNA fragments derived from pSH5 and the fragments from pMHI thus obtained were dissolved into 10 µl of each TE, respectively. Next, 3.5 µl of each solution was mixed and the DNA fragments therein were ligated by reacting the resultant mixture at 10°C for one hour utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.). The combined DNA was used to transform *E. coli* (strain N99cl+), and plasmid DNA was purified from the obtained transformants. This plasmid is pSH6 formed by inserting a fragment of the complete synthetic MAP gene, which obtained by reacting with XbaI and BanIII, into the plasmid pSH5.

A Step of Inserting Signal Sequence Gene of OmpA into pSH6

- Each single-stranded DNA of complementary DNA fragments having a base sequences shown in Fig. 1 was synthesized according to phosphoramidite method utilizing a DNA synthesizer (manufactured by Applied Biosystems Japan, 381A type). One microgram of each synthesized single-stranded DNA was incubated in 50 µl of said kinase solution containing 10 units of T4 kinase (manufactured by Toyobo Co., Ltd.) at 37°C for one hour to phosphorylate 5'-terminal of the DNA. Each solution containing the

phosphorylated single-stranded DNA were mixed and the resultant solution was heated at 60°C for 20 minutes and allowed to stand at room temperature for 20 minutes for annealing to obtain double-stranded DNA. The obtained double-stranded DNA was collected by ethanol precipitation and dissolved in 10 µl of TE.

On the other hand, 1 µg of the plasmid pSH6 was incubated in 50 µl of High Buffer containing 10 units of each restriction enzyme NdeI and XbaI (both manufactured by Nippon Gene Co., Ltd.) at 37°C for one hour for digestion. The cleaved DNA was collected by subjecting the reacted solution to phenol-chloroform treatment and the following ethanol precipitation. The collected DNA was further dissolved in 10 µl of TE.

Three point five micro liter of the TE solution containing the annealed synthetic DNA and also 3.5 µl of the TE solution containing the cleaved pSH6 was mixed. The mixture was reacted at 10°C for two hours by utilizing the ligation kit (manufactured by Takara Syuzo Co., Ltd.) to combine the synthetic DNA and the cleaved DNA. The combined DNA was used to transform E.coli (strain N99cl+), and plasmid DNA was purified from the obtained transformants. This plasmid is plasmid pSH7 formed by inserting the gene of OmpA signal sequence into pSH6.

Expression of MAP Utilizing E.coli transformed with The Plasmid pSH6

E.coli (strain MM294) was transformed by the plasmid pSH6. The obtained transformants were cultured in 5 ml of LB medium (a mixture of 1% bact. trypton, 0.5% bact. yeast extract, 1% sodium chloride, and 0.1% glucose) containing 50 µg/ml of ampicillin at 30°C under the aerobic condition overnight. Next, the medium was added into M9CA medium (a mixture of 6g/l of disodium phosphate, 3g/l of potassium phosphate, 0.5g/l of sodium chloride, 1g/l of ammonium chloride, 2mM of magnesium sulphate, 0.1mM of calcium chloride, and 2g/l of glucose) containing 50 µg/ml of ampicillin and 4 µg/ml of thiamine hydrochloride to achieve a final concentration of 1%. The resultant solution was cultured at 30°C under the aerobic condition. Growth rate of the transformants was almost the same as that of E.coli transformants (strain MM294) which was transformed with plasmid pSH5 containing no MAP gene. It is apparent from this fact that the plasmid pSH6 did not affect the growth of E.coli.

When the absorbance of the medium at 550nm achieved 0.8, M9CA medium which had already been heated to 55°C was added to the medium in equivalent volume to accelerate the production of MAP. After that, the solution was further cultured at 42°C under the aerobic condition to have MAP accumulated in E.coli bodies.

After culture was terminated, the E.coli bodies were collected by centrifugation and suspended in 0.9% aqueous NaCl solution which is equivalent to the medium in volume. This suspension was further centrifuged to collect the E.coli bodies. The collected bodies were further suspended in 0.9% aqueous sodium chloride solution, followed by braking by means of a ultra sonic vibrator. The obtained sample was subjected to enzyme-linked immunosorbent assay (ELISA). The result was that 20 µg/l of MAP was produced.

Expression of MAP Utilizing E.coli Transformed with Plasmid pSH7

E.coli (strain MM294) was transformed by the plasmid pSH7. The obtained transformants were cultured with shaking in 5 ml of LB medium containing 50 µg/ml of ampicillin under the aerobic condition at 30°C overnight in the same manner as for pSH6. Next, the medium was added into M9CA medium containing 50 µg/ml of ampicillin and 4 µg/ml of thiamine hydrochloride to achieve a final concentration of 1%, followed by culture at 30°C under the aerobic condition in the same manner as for pSH6. The growth rate of the transformants was almost the same as that of E.coli transformants (strain MM294) which was transformed with the plasmid pSH5 containing no MAP gene. This fact reveals that the plasmid pSH7 did not affect the growth of the E.coli.

When absorbance of the medium at 550nm achieved 0.8, M9CA medium which had been already heated to 55°C was added to the medium in equivalent volume to accelerate MAP production. After that, the resultant medium was further cultured at 42°C under the aerobic condition to have MAP accumulated in the medium.

After the culture was terminated, the *E. coli* bodies were separated by centrifugation, and the residual solution was dialyzed with water. The dialyzed solution was subjected to an immunological analysis (ELISA) utilizing anti-MAP antibodies to detect extracellularly 200 µg/l of MAP in the solution. Additionally, western blotting analysis was performed to confirm presence of a protein having the same molecular weight as that of MAP in the solution.

Claims

1. A gene comprising the following base sequence:

10

15

20

25

30

35

40

45

50

55

```

GCGCCTACTC TAGAAACCAT CGCTTCTCTG GACCTGAACA
CGCGGATGAG ATCTTTGGTA GCGAAGAGAC CTGGACTTGT

ACCCGACCAC CTACCTGTCT TTCATAACGA ATATCCGTAC
TGGGCTGGTG GATGGACAGA AAGTATTGCT TATAGGCATG

GAAAGTCGCA GACAAAACCG AACAGTGTAC CATCCAGAAA
CTTTCAGCGT CTGTTTTGGC TTGTCACATG GTAGGTCTTT

ATCTCTAAAA CCTTCACCCA GCGTTACTCT TACATAGACT
TAGAGATTTT GGAAGTGGGT CGCAATGAGA ATGTATCTGA

TGATCGTGAG CTCGACGCAG AAAATCACCC TAGCTATCGA
ACTAGCACTC GAGCTGCGTC TTTTAGTGGG ATCGATAGCT

CATGGCTGAC CTGTACGTTT TGGGTTACTC TGACATCGCT
GTACCGACTG GACATGCAAG ACCCAATGAG ACTGTAGCGA

AATAACAAGG GTCGTGCTTT CTTCTTCAAA GACGTGACTG
TTATTGTTCC CAGCACGAAA GAAGAAGTTT CTGCACTGAC

AGGCTGTTGC GAACAATTTT TTCCCGGGAG CTACAGGTAC
TCCGACAACG CTTGTAAAG AAGGGCCCTC GATGTCCATG

TAATCGTATC AAATTAACCT TTACAGGTTT TTATGGCGAT
ATTAGCATAG TTTAATTGGA AATGTCCAAG AATACCGCTA

CTCGAGAAAA ACGGCGGACT ACGTAAGGAC AATCCCCTAG
GAGCTCTTTT TGCCGCCCTG TGCATTCTCTG TTAGGGGATC

GTATCTTCCG TCTGGAAAAC TCGATAGTTA ACATTTATGG
CATAGAAGGC AGACCTTTTG AGCTATCAAT TGTAATAACC

CAAAGCTGGT GACGTTAAAA AACAGGCTAA ATTCTTCTTA
GTTTCGACCA CTGCAATTTT TTGTCCGATT TAAGAAGAAT

CTGGCTATCC AGATGGTTTC GGAGGCTGCG CGCTTTAAGT
GACCGATAGG TCTACCAAAG CCTCCGACGC GCGAAATTCA

ATATCAGTGA CAAAATCCCG TCTGAAAAAT ACGAAGAAGT
TATAGTCACT GTTTTAGGGC AGACTTTTTA TGCTTCTTCA

TACCGTTGAC GAATACATGA CCGCTCTGGA AAACAACCTGG
ATGGCAACTG CTTATGTACT GCGAGACCT TTTGTTGACC

GCTAAACTGT CTACGGCCGT ATACAACTCT AAGCCTTCTA
CGATTTGACA GATGCCGCGA TATGTTGAGA TTCGGAAGAT

CCACCACCGC TACCAAATGT CAGCTGGCTA CCTCTCCGGT
GGTGGTGGCG ATGGTTTACA GTCGACCGAT GGAGAGGCCA

TACCATCTCT CCGTGGATAT TCAAAACCGT CGAGGAAATC
ATGGTAGAGA GGCACCTATA AGTTTTGGCA GCTCCTTTAG

AAACTGGTTA TGGGTCTGCT TAAGTCTTCT TAATAA
TTTGACCAAT ACCCAGACGA ATTCAGAAGA ATTATT

```

said base sequence coding for MAP, wherein the gene includes in the upstream of the base sequence a gene which comprises the following base sequence:

TATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCT
 ACTTTTTCTGTCGATAGCGCTAACGTCACCGTGACCGA
 GGTTCGCTACCGTAGCGCAGGCC GCGCCTACT
 CCAAAGCGATGGCATCGCGTCCGG CCGGATGAGATC

5

and which codes for OmpA signal sequence.

2. Recombinant plasmid having E.coli expression systems and the gene described in the claim 1 inserted.
3. Recombinant plasmid including P_L promotor derived from E.coli lambda-phage, cl_{857} repressor gene, and also the gene described in the claim 1 such that the gene can express in the E.coli.
4. E.coli transformant comprising the plasmid described in the claim 2 or 3.
5. A method for producing MAP comprising:
 a step of culturing the E.coli transformants described in the claim 4 to express the gene described in the claim 1 which is introduced in said transformants and to induce them to produce MAP, and
 a step of separating and purifying MAP which is extracellularly produced.

20

25

30

35

40

45

50

55

Patentansprüche

1. Gen, umfassend die folgende Basensequenz:

5
 GCGCCTACTC TAGAAACCAT CGCTTCTCTG GACCTGAACA
 CGCGGATGAG ATCTTTGGTA GCGAAGAGAC CTGGACTTGT
 10
 ACCCGACCAC CTACCTGTCT TTCATAACGA ATATCCGTAC
 TGGGCTGGTG GATGGACAGA AAGTATTGCT TATAGGCATG
 GAAAGTCGCA GACAAAACCG AACAGTGATC CATCCAGAAA
 CTTTCAGCGT CTGTTTTGGC TTGTCACATG GTAGGTCTTT
 15
 ATCTCTAAAA CCTTCACCCA GCGTTACTCT TACATAGACT
 TAGAGATTTT GGAAGTGGGT CGCAATGAGA ATGTATCTGA
 TGATCGTGAG CTCGACGCAG AAAATCAGCC TAGCTATCGA
 ACTAGCACTC GAGCTGCGTC TTTTAGTGGG ATCGATAGCT
 CATGGCTGAC CTGTACGTTT TGGGTTACTC TGACATCGCT
 GTACCGACTG GACATGCAAG ACCCAATGAG ACTGTAGCGA
 20
 AATAACAAGG GTCGTGCTTT CTTCTTCAA GACGTGACTG
 TTATTGTTCC CAGCACGAAA GAAGAAGTTT CTGCACTGAC
 AGGCTGTTGC GAACAATTTT TTCCCGGGAG CTACAGGTAC
 TCCGACAACG CTTGTAAAG AAGGGCCCTC GATGTCCATG
 25
 TAATCGTATC AAATTAACCT TTACAGGTTT TTATGGCGAT
 ATTAGCATAG TTTAATTGGA AATGTCCAAG AATACCGCTA
 CTCGAGAAAA ACGGCGGACT ACGTAAGGAC AATCCCCTAG
 GAGCTCTTTT TGCCGCCTGA TGCATTCTG TTAGGGGATC
 30
 GTATCTTCCG TCTGGAAAAC TCGATAGTTA ACATTTATGG
 CATAGAAGGC AGACCTTTTG AGCTATCAAT TGTAAATACC
 CAAAGCTGGT GACGTAAAAA AACAGGCTAA ATTCTTCTTA
 GTTTCGACCA CTGCAATTTT TTGTCCGATT TAAGAAGAA
 35
 CTGGCTATCC AGATGGTTTC GGAGGCTGCG CGCTTTAAGT
 GACCGATAGG TCTACCAAAG CCTCCGACGC GCGAAATTCA
 ATATCAGTGA CAAAATCCCG TCTGAAAAAT ACGAAGAAGT
 TATAGTCACT GTTTTAGGGC AGACTTTTTTA TGCTTCTTCA
 TACCGTTGAC GAATACATGA CCGCTCTGGA AAACAACCTG
 40
 ATGGCAACTG CTTATGTACT GGCGAGACCT TTTGTTGACC
 GCTAAACTGT CTACGGCCGT ATACAACTCT AAGCCTTCTA
 CGATTTGACA GATGCCGGCA TATGTTGAGA TTCGGAAGAT
 CCACCACCGC TACCAAATGT CAGCTGGCTA CCTCTCCGGT
 GGTGGTGGCG ATGGTTTACA GTCGACCGAT GGAGAGGCCA
 45
 TACCATCTCT CCGTGGATAT TCAAAACCGT CGAGGAAATC
 ATGGTAGAGA GGCACCTATA AGTTTTGGCA GCTCCTTTAG
 AAAGTGGTTA TGGGTCTGCT TAAGTCTTCT TAATAA
 TTTGACCAAT ACCCAGACGA ATTCAGAAGA ATTATT

50

wobei die Basensequenz für MAP codiert, wobei das Gen stromaufwärts von der Basensequenz ein Gen enthält, welches die folgende Basensequenz umfaßt:

55

TATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCT
 ACTTTTTTCTGTCGATAGCGCTAACGTCACCGTGACCGA
 GGTTCGCTACCGTAGCGCAGGCC GCGCCTACT
 CCAAAGCGATGGCATCGCGTCCGG CGCGGATGAGATC

5

und welche für eine OmpA-Signalsequenz codiert.

- 10 2. Rekombinantes Plasmid mit E. coli-Expressionssystemen und dem in Anspruch 1 beschriebenen eingefügten Gen.
3. Rekombinantes Plasmid, das einen von der E. coli-Lambda-Phage abgeleiteten P_L-Promotor, das cl₈₅₇-Repressorgen und auch das in Anspruch 1 beschriebene Gen enthält, so daß das Gen in E. coli exprimiert werden kann.
- 15 4. E. coli-Transformante, umfassend das in Anspruch 2 oder 3 beschriebene Plasmid.
5. Verfahren zur Herstellung von MAP, umfassend:
 20 einen Schritt zur Kultivierung von den in Anspruch 4 beschriebenen E. coli-Transformanten zur Expression des in Anspruch 1 beschriebenen Gens, welches in den Transformanten eingeführt wird, und um diese zur Herstellung von MAP zu veranlassen, und
 einen Schritt zur Abtrennung und Reinigung von MAP, welches extrazellulär gebildet wird.

25

30

35

40

45

50

55

Rev indications

1. Gène comprenant la séquence de bases suivante :

```

5      GCGCCTACTC TAGAAACCAT CGCTTCTCTG GACCTGAACA
      CCGCGATGAG ATCTTTGGTA GCGAAGAGAC CTGGACTTGT

      ACCCGACCAC CTACCTGTCT TTCATAACGA ATATCCGTAC
      TGGGCTGGTG GATGGACAGA AAGTATTGCT TATAGGCATG

10     GAAAGTCGCA GACAAAACCG AACAGTGTAC CATCCAGAAA
      CTTTCAGCGT CTGTTTTTGGC TTGTCACATG GTAGGTCTTT

      ATCTCTAAAA CTTTCACCCA GCGTTACTCT TACATAGACT
      TAGAGATTTT GGAAGTGGGT CGCAATGAGA ATGTATCTGA

15     TGATCGTGAG CTCGACGCAG AAAATCACCC TAGCTATCGA
      ACTAGCACTC GAGCTGCGTC TTTTAGTGGG ATCGATAGCT

      CATGGCTGAC CTGTACGTTT TGGGTTACTC TGACATCGCT
      CTACCGACTG GACATGCAAG ACCCAATGAG ACTGTAGCGA

20     AATAACAAGG GTCGTGCTTT CTTCTTCAAA GACGTGACTG
      TTATTGTTCC CAGCAAGAAA GAAGAAGTTT CTGCACTGAC

      AGGCTGTTGC GAACAATTTT TTCCCGGGAG CTACAGGTAC
      TCCGACAACG CTTGTTAAAG AAGGGCCCTC GATGTCCATG

25     TAATCGTATC AAATTAACCT TTACAGGTTT TTATGGCGAT
      ATTAGCATAG TTTAATTGGA AATGTCCAAG AATACCGCTA

      CTCGAGAAAA ACGGCGGACT ACGTAAGGAC AATCCCGTAG
      GAGCTCTTTT TGCCGCGCTG TGCAATTCCTG TTAGGGGATC

30     GTATCTTCCG TCTGGAAGAC TCGATAGTTA ACATTTATGG
      CATAGAAGGC AGACCTTTTG AGCTATCAAT TGTAAATACC

      CAAAGCTGGT GACGTTAAAA AACAGGCTAA ATTCTTCTTA
      GTTTCGACCA CTGCAATTTT TTGTCCGATT TAAGAAGAAT

      CTGGCTATCC AGATGGTTTC GGAGGCTGCG CGCTTTAAGT
      GACCGATAGG TCTACCAAAG CCTCCGACGC GCGAAATTCA

35     ATATCAGTGA CAAAATCCCG TCTGAAAAAT ACGAAGAAGT
      TATAGTCACT GTTTTAGGGC AGACTTTTTTA TGCTTCTTCA

      TACCGTTGAC GAATACATGA CCGCTCTGGA AAACAACTGG
      ATGGCAACTG CTTATGTACT GGCGAGACCT TTTGTTGACC

40     GCTAAACTGT CTACGGCCGT ATACAACTCT AAGCCTTCTA
      CGATTTGACA GATGCCGGCA TATGTTGAGA TTCGGAAGAT

      CCACCACCGC TACCAAATGT CAGCTGGCTA CCTCTCCGGT
      GGTGGTGGCG ATGGTTTACA GTCGACCGAT GGAGAGGCCA

45     TACCATCTCT CCGTGGATAT TCAAAACCGT CGAGGAATC
      ATGGTAGAGA GGCACTATA AGTTTTGGCA GCTCCTTTAG

      AAACCTGGTTA TGGGTCTGCT TAAGTCTTCT TAATTA
      TTTGACCAAT ACCCAGACGA ATTCAGAAGA ATTATT

```

- 50 ladite séquence de bases codant pour la protéine anti-virale de Mirabilis (PAM), le gène renfermant en amont de la séquence de bases un gène qui comprend la séquence de bases suivante :

```

55     TATGAAAAAGACAGCTATCGCGATTGCAAGTGGCACTGGCT
      ACTTTTTCTGTCCGATAGCGCTAACGTCACCGTGACCGA

      GGTTCGCTACCGTAGCGCAGGCC GCGCCTACT
      CCAAAGCGATGGCATCGCGTCCGG CGCGGATGAGATC

```

et qui code pour la séquence signal de OmpA.

2. Plasmide recombiné dans lequel sont insérés des systèmes d'expression de E. coli et le gène décrit dans la revendication 1.
- 5 3. Plasmide recombiné renfermant un promoteur P_L provenant du phage lambda de E. coli, un gène de répresseur $c_{\lambda s7}$, et également le gène décrit dans la revendication 1, de façon que le gène puisse s'exprimer dans E. coli.
- 10 4. Transformant de E. coli, comprenant le plasmide décrit dans la revendication 2 ou 3.
5. Procédé de production de PAM, comprenant les étapes consistant à :
cultiver les transformants de E. coli décrits dans la revendication 4, pour exprimer le gène décrit dans la revendication 1, qui est introduit dans lesdits transformants, et amener ces derniers à produire
15 de la PAM, et
séparer et purifier la PAM qui est produite de manière extracellulaire.

20

25

30

35

40

45

50

55

Fig. 1

NdeI
 MetLysLysThrAlaIleAlaIleAlaValAlaLeuAlaGlyPheAlaThrValAlaGlnAla AlaProThrLeu XbaI
 TATGAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCC GCGCCTACT
 ACTTTTCTGTGCGATAGCGCTAACGTACCGTGACCGGACCAAGCGATGGCATCGCGTCCGG CCGGGATGAGATC
 ompA signal MAP

Fig. 3

EcoRI PstI Sali SD Nde I XbaI BanIII HindIII
 AATTCCTGCAAGTCGACAGGAAACACATATGGCGCCTACTCTAGAAAATCGATAAA
 GGACGTCAGCTGTCCCTTTGTGTATACCGCGGATGAGATCTTTTAGCTATTTTCGA

GCGCCTACTC TAGAAACCAT CGCTTCTCTG GACCTGAACA ACCCGACCAC CTACCTGTCT
 CGCGGATGAG ATCTTTGGTA GCGAAGAGAC CTGGACTTGT TGGGCTGGTG GATGGACAGA

 TTCATAACGA ATATCCGTAC GAAAGTCGCA GACAAAACCG AACAGTGTAC CATCCAGAAA
 AAGTATTGCT TATAGGCATG CTTTCAGCGT CTGTTTTGGC TTGTCACATG GTAGGTCTTT

 ATCTCTAAAA CCTTCACCCA GCGTTACTCT TACATAGACT TGATCGTGAG CTCGACGCAG
 TAGAGATTTT GGAAGTGGGT CGCAATGAGA ATGTATCTGA ACTAGCACTC GACCTGCGTC

 AAAATCACCC TAGCTATCGA CATGGCTGAC CTGTACGTTT TGGGTTACTC TGACATCGCT
 TTTTAGTGGG ATCGATAGCT GTACCGACTG GACATGCAAG ACCCAATGAG ACTGTAGCGA

 AATAACAAGG GTCGTGCTTT CTTCTTCAAA GACGTGACTG AGGCTGTTC GAACAATTTT
 TTATTGTTCC CAGCACGAAA GAAGAAGTTT CTGCACTGAC TCCGACAACG CTTGTTAAAG

 TTCCCGGGAG CTACAGGTAC TAATCGTATC AAATTAACCT TTACAGGTTT TTATGGCGAT
 AAGGGCCCTC GATGTCCATG ATTAGCATAG TTTAATTGGA AATGTCCAAG AATACCGCTA

 CTCGAGAAAA ACGGCGGACT ACGTAAGGAC AATCCCCTAG GTATCTTCCG TCTGGAAAAC
 GAGCTCTTTT TGCCGCCTGA TGCATTCTCG TTAGGGGATC CATAGAAGGC AGACCTTTTG

 TCGATAGTTA ACATTTATGG CAAAGCTGGT GACGTTAAAA AACAGGCTAA ATTCTTCTTA
 AGCTATCAAT GTAAATACC GTTTCGACCA CTGCAATTTT TTGTCCGATT TAAGAAGAAT

 CTGGCTATCC AGATGGTTTC GGAGGCTGCG CGCTTTAAGT ATATCAGTGA CAAAATCCCG
 GACCGATAGG TCTACCAAAG CCTCCGACGC GCGAAATTCA TATAGTCACT GTTTTAGGGC

 TCTGAAAAAT ACGAAGAAGT TACCGTTGAC GAATACATGA CCGCTCTGGA AAACAACTGG
 AGACTTTTTA TGCTTCTTCA ATGGCAACTG CTTATGTACT GGCGAGACCT TTTGTTGACC

 GCTAAACTGT CTACGGCCGT ATACAACTCT AAGCCTTCTA CCACCACCGC TACCAAATGT
 CGATTTGACA GATGCCGCCA TATGTTGAGA TTCGGAAGAT GGTGGTGGCG ATGGTTTACA

 CAGCTGGCTA CCTCTCCCCT TACCATCTCT CCGTGGATAT TCAAAACCGT CGAGGAAATC
 GTCGACCGAT GGAGAGGCCA ATGGTAGAGA GGCACCTATA AGTTTTGGCA GCTCCTTTAG

 AAAGTGGTTA TGGGTCTGCT TAAGTCTTCT TAATAA
 TTTGACCAAT ACCCAGACGA ATTCAGAAGA ATTATT

Fig. 2




FIG. 4A




FIG. 4B




FIG. 4C